Susan Zolla-Pazner

USPTO Granted Patents = 15 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 2.9

ph-index = 5

Forward Citations = 67(Granted Patents)

Company Filing History:

University of Massachusetts

Colorado State University Research Foundation

patents

5. 1 out of 270

Icahn School of Medicine at Mount Sinai

U.S. Army Medical Research and Materiel Command

patents

8. 2 out of 832,912

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2020

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10568969 - Immunogenic polypeptides (2020-02-25),

2. 9988424 - Immunogens comprising human immunodeficiency virus V1/V2 polypeptides (2018-06-05),

3. 9611294 - Peptides mimicking HIV-1 viral epitopes in the V2 loop for the GP120 surface envelope glycoprotein (2017-04-04),

4. 9534020 - Immunogenic polypeptides comprising a modified loop peptide presenting the HIV-1 GP120 3074 mAb epitope and scaffold proteins containing said peptide (2017-01-03),

5. 9335325 - [object Object] (2016-05-10),

6. 8961987 - Immunogen comprising the HIV GP120 V3 loop in a conformation that induces broadly neutralizing antibodies (2015-02-24),

7. 7847085 - Recombinant HIV-1 gp120 immunogen with three different V3 loops from viruses of different clades (2010-12-07),

8. 7807182 - Early detection of mycobacterial disease using peptides (2010-10-05),

9. 7745141 - Mycobacterial proteins as early antigens for serodiagnosis and vaccines (2010-06-29),

10. 7638319 - Method for determining co-receptor selectivity of Human Immunodeficiency Virus-1 (2009-12-29),

11. 6506384 - Early detection of mycobacterial disease (2003-01-14),

12. 6245331 - Early detection of mycobacterial disease (2001-06-12),

13. 6241986 - Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV (2001-06-05),

14. 5914109 - Heterohybridomas producing human monoclonal antibodies to HIV-1 (1999-06-22),

15. 5731189 - Human monoclonal antibodies to human immunodeficiency virus (1998-03-24),

Title: Susan Zolla-Pazner: Innovator in Immunogenic Polypeptides

Introduction

Susan Zolla-Pazner is a prominent inventor based in New York, NY, known for her significant contributions to the field of immunology. With a remarkable portfolio of 15 patents, she has made strides in developing innovative immunogenic polypeptides that have the potential to advance vaccine technology and therapeutic applications.

Latest Patents

One of her latest patents focuses on isolated immunogenic polypeptides. This invention relates to a scaffold polypeptide that includes a hairpin loop modified to incorporate one or more epitopes that are heterologous to the scaffold polypeptide. The design allows for self-assembly with other scaffold polypeptides to form a trimeric structure, which constrains the epitopes to a conformation similar to native pathogen epitopes. Another aspect of her work involves an isolated immunogenic polypeptide that forms a pentameric structure, enhancing the binding capability to antibodies reactive to native pathogen epitopes. Additionally, she has developed immunogens comprising human immunodeficiency virus V1/V2 polypeptides, further showcasing her expertise in this critical area of research.

Career Highlights

Throughout her career, Susan Zolla-Pazner has been affiliated with prestigious institutions such as New York University and the University of Massachusetts. Her work has not only contributed to scientific knowledge but has also paved the way for practical applications in immunology and vaccine development.

Collaborations

Susan has collaborated with notable colleagues, including Suman Laal and Miroslaw K Gorny, enhancing the impact of her research through teamwork and shared expertise.

Conclusion

Susan Zolla-Pazner stands out as a leading inventor in the field of immunogenic polypeptides, with a strong record of patents and collaborations that highlight her contributions to science and medicine. Her innovative work continues to influence the development of effective immunotherapies and vaccines.

This text is generated by artificial intelligence and may not be accurate.